Comments

Keros Therapeutics

KROSNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$52.17
00.00%
Last update: 4:52 PM
15 minutes delayed
Keros Therapeutics (KROS) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$105.00
Lowest Price Target1
$60.00
Consensus Price Target1
$90.38

want to know what
the Bulls & Bears Say?

Keros Therapeutics (NASDAQ:KROS) Stock, Analyst Ratings, Price Targets, Forecasts

Keros Therapeutics Inc has a consensus price target of $90.38 based on the ratings of 9 analysts. The high is $105 issued by Piper Sandler on March 27, 2024. The low is $60 issued by Wells Fargo on December 8, 2023. The 3 most-recent analyst ratings were released by Oppenheimer, Truist Securities, and HC Wainwright & Co. on June 25, 2024, June 18, 2024, and June 18, 2024, respectively. With an average price target of $100.67 between Oppenheimer, Truist Securities, and HC Wainwright & Co., there's an implied 103.92% upside for Keros Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Mar
0
0
0
0
May
1
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Oppenheimer
Truist Securities
HC Wainwright & Co.
Piper Sandler
Wells Fargo

1calculated from analyst ratings

Analyst Ratings for Keros Therapeutics

Buy NowGet Alert
06/25/2024Buy Now106.62%Oppenheimer
Andreas Argyrides
 → $102Initiates → OutperformGet Alert
06/18/2024Buy Now102.57%Truist Securities
Srikripa Devarakonda
$100 → $100MaintainsBuyGet Alert
06/18/2024Buy Now102.57%HC Wainwright & Co.
Andrew Fein
$100 → $100ReiteratesBuy → BuyGet Alert
05/09/2024Buy Now102.57%HC Wainwright & Co.
Andrew Fein
 → $100ReiteratesBuy → BuyGet Alert
03/27/2024Buy Now112.7%Piper Sandler
Joseph Catanzaro
 → $105MaintainsOverweightGet Alert
03/13/2024Buy Now102.57%Truist Securities
Srikripa Devarakonda
 → $100ReiteratesBuy → BuyGet Alert
03/01/2024Buy Now102.57%HC Wainwright & Co.
Andrew Fein
 → $100ReiteratesBuy → BuyGet Alert
12/08/2023Buy Now21.54%Wells Fargo
Tiago Fauth
 → $60Initiates → OverweightGet Alert
11/13/2023Buy Now74.21%Wedbush
Andreas Argyrides
 → $86ReiteratesOutperform → OutperformGet Alert
08/31/2023Buy Now74.21%Wedbush
Andreas Argyrides
 → $86ReiteratesOutperform → OutperformGet Alert
08/09/2023Buy Now102.57%HC Wainwright & Co.
Andrew Fein
 → $100ReiteratesBuy → BuyGet Alert
08/08/2023Buy Now74.21%Wedbush
Andreas Argyrides
 → $86ReiteratesOutperform → OutperformGet Alert
08/07/2023Buy Now102.57%HC Wainwright & Co.
Andrew Fein
 → $100Reiterates → BuyGet Alert
07/31/2023Buy Now74.21%Wedbush
Andreas Argyrides
 → $86Initiates → OutperformGet Alert
07/26/2023Buy Now31.67%B of A Securities
Greg Harrison
 → $65Initiates → BuyGet Alert
06/09/2023Buy Now102.57%HC Wainwright & Co.
Andrew Fein
 → $100Reiterates → BuyGet Alert
05/08/2023Buy Now102.57%HC Wainwright & Co.
Andrew Fein
 → $100Reiterates → BuyGet Alert
05/05/2023Buy Now122.83%Piper Sandler
Joseph Catanzaro
$120 → $110MaintainsOverweightGet Alert
03/06/2023Buy Now102.57%HC Wainwright & Co.
Andrew Fein
 → $100Reiterates → BuyGet Alert
02/14/2023Buy Now—Cowen & Co.
Tyler Van Buren
—Initiates → OutperformGet Alert
12/13/2022Buy Now112.7%BTIG
Julian Harrison
$95 → $105MaintainsBuyGet Alert
10/18/2022Buy Now102.57%Truist Securities
Srikripa Devarakonda
 → $100Initiates → BuyGet Alert
07/26/2022Buy Now62.06%BTIG
Julian Harrison
 → $80Initiates → BuyGet Alert

FAQ

Q

What is the target price for Keros Therapeutics (KROS) stock?

A

The latest price target for Keros Therapeutics (NASDAQ:KROS) was reported by Oppenheimer on June 25, 2024. The analyst firm set a price target for $102.00 expecting KROS to rise to within 12 months (a possible 95.51% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Keros Therapeutics (KROS)?

A

The latest analyst rating for Keros Therapeutics (NASDAQ:KROS) was provided by Oppenheimer, and Keros Therapeutics initiated their outperform rating.

Q

When was the last upgrade for Keros Therapeutics (KROS)?

A

There is no last upgrade for Keros Therapeutics

Q

When was the last downgrade for Keros Therapeutics (KROS)?

A

There is no last downgrade for Keros Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Keros Therapeutics (KROS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Keros Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Keros Therapeutics was filed on June 25, 2024 so you should expect the next rating to be made available sometime around June 25, 2025.

Q

Is the Analyst Rating Keros Therapeutics (KROS) correct?

A

While ratings are subjective and will change, the latest Keros Therapeutics (KROS) rating was a initiated with a price target of $0.00 to $102.00. The current price Keros Therapeutics (KROS) is trading at is $52.17, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch